POSC110 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-Year Pacific Data
Jan 1, 2022, 00:00 AM
10.1016/j.jval.2021.11.515
https://www.valueinhealthjournal.com/article/S1098-3015(21)02310-X/fulltext
Section Title :
Section Order :
10048
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)02310-X&doi=10.1016/j.jval.2021.11.515